Literature DB >> 15377828

Biochemical and immunological properties of cytokines conjugated to dendritic polymers.

S C Lee1, R Parthasarathy, K Botwin, D Kunneman, E Rowold, G Lange, J Klover, A Abegg, J Zobel, T Beck, T Miller, W Hood, J Monahan, J P McKearn, R Jansson, C F Voliva.   

Abstract

Here we describe a post-translational modification of SC-63032, a variant of the species restricted, multi-lineage hematopoeitic factor human interleukin-3 (hIL-3). We have made two new dendritic polymer (polyamidoamine or PAMAM dendrimers, generation 5)-SC-63032 bioconjugates. Using two distinct chemistries (one of which is novel to this work), we achieved site-specific conjugation with respect to the amino acid in the proteins ligated to the dendrimers. In both bioconjugates, conjugated cytokine maintains its ability to bind the hIL-3 alpha receptor subunit, but is significantly (about 10-fold) less potent in inducing hIL-3 dependent in vitro cell proliferation than is the free cytokine. In vivo data indicates that conjugation decreases the immunogenicity of the conjugated cytokine modestly. In the absence of pharmacokinetic or biodistribution effects associated with the bioconjugates that increase their potency in vivo (which can only be tested in a higher primate, due to the species restriction of hIL-3 and its derivatives), these immune mitigation effects may be too small to be therapeutically significant. Though unmodified PAMAM dendrimers fail to elicit an antibody response in mice, protein conjugation to dendrimers haptenizes them, and a dendrimer-specific antibody response is produced. In toto, the principal limitation of the dendrimer-cytokine bioconjugates herein is in their reduced receptor affinity and potency in vitro. Were the in vivo potency of the bioconjugates to parallel the in vitro potency of the conjugates reported here, it is likely that particular dendrimer bioconjugates could not justify their higher costs of goods relative to the parent SC-63032 molecule, though retention of SC-63032 biological activities in conjugates suggests that other cytokine-dendrimer bioconjugates may be bioactive. This is good news to the nanotechnology community, in as much as PAMAM dendrimers are among the monodisperse polymeric nanomaterials available, and these results show that they can be used successfully in conjugates to bioactive proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377828     DOI: 10.1023/B:BMMD.0000042048.18186.ff

Source DB:  PubMed          Journal:  Biomed Microdevices        ISSN: 1387-2176            Impact factor:   2.838


  10 in total

1.  Engineering functional protein interfaces for immunologically modified field effect transistor (ImmunoFET) by molecular genetic means.

Authors:  Edward Eteshola; Matthew T Keener; Mark Elias; John Shapiro; Leonard J Brillson; Bharat Bhushan; Stephen Craig Lee
Journal:  J R Soc Interface       Date:  2008-01-06       Impact factor: 4.118

Review 2.  Nanoparticles and the immune system.

Authors:  Banu S Zolnik; Africa González-Fernández; Nakissa Sadrieh; Marina A Dobrovolskaia
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

Review 3.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

4.  Synthesis of Hydrophilic Aminooxy Linkers and Multivalent Cores for Chemoselective Aldehyde/Ketone Conjugation.

Authors:  Katherine D McReynolds; Dustin Dimas; Hoang Le
Journal:  Tetrahedron Lett       Date:  2014-04-02       Impact factor: 2.415

Review 5.  Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.

Authors:  Piper A Rawding; Jiyoon Bu; Jianxin Wang; Da Won Kim; Adam J Drelich; Youngsoo Kim; Seungpyo Hong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-08-19

Review 6.  Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-07       Impact factor: 4.219

Review 7.  Therapeutic interventions in sepsis: current and anticipated pharmacological agents.

Authors:  Prashant Shukla; G Madhava Rao; Gitu Pandey; Shweta Sharma; Naresh Mittapelly; Ranjita Shegokar; Prabhat Ranjan Mishra
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 8.  Challenges in development of nanoparticle-based therapeutics.

Authors:  Neil Desai
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 9.  Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications.

Authors:  Ana Santos; Francisco Veiga; Ana Figueiras
Journal:  Materials (Basel)       Date:  2019-12-21       Impact factor: 3.623

Review 10.  Engineered Nanomaterials and Type I Allergic Hypersensitivity Reactions.

Authors:  Nasser B Alsaleh; Jared M Brown
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.